Determining Prevention of Nasal Polyp Recurrence in AERD Patients Using Aspirin

Overview

About this study

The purpose of this study is to investigate the mechanism through which aspirin works for the prevention of nasal polyp recurrence in AERD patients, while comparing two aspirin doses: 325 mg once-daily or 650 mg twice daily dose of aspirin.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 and < 70 years.
  • Any gender.
  • Patients with physician-diagnosed AERD (including a physician diagnosis of bilateral nasal polyposis, and at least one NSAID-induced reaction that caused respiratory symptoms).
  • Patients with nasal polyps and no AERD (with and without asthma).
  • Patients who require endoscopic sinus surgery (ESS) for treatment of chronic rhinosinusitis and sinonasal polyposis as part of their standard of care treatment.

Exclusion Criteria:

  • Patients under the age of 18 years and above 70 years.
  • Patients who are or intend to get pregnant during the course of the study or those who are breastfeeding.
  • Patients with mental or legal incapacitation.
  • Patients with acute of chronic kidney or liver disease either self-reported or physician-diagnosed.
  • Patients with anemia requiring work-up up (hemoglobin < 10 mg/dL).
  • Patients with an active peptic ulcer disease.
  • Patients with bleeding-disorder or G6PD deficiency.
  • Patients with a planned surgical procedure during the 1-year study period.

Eligibility last updated 8/16/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elina Jerschow, M.D., M.S.

Open for enrollment

Contact information:

Eboni Patten C.S.T.

(507) 266-7035

Patten.Eboni@mayo.edu

More information

Publications

Publications are currently not available